Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | YWHAH | Q04917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6090135 | 0.91 | TP53 (0.46) | TP53POLBPLA2G2AGRIN1GRIN2B | |
| SCHEMBL6089633 | 0.84 | TP53 (0.48) | TP53POLBPLA2G2AGRIN1GRIN2B | |
| SCHEMBL6090994 | 0.81 | TP53 (0.46) | TP53POLBRXFP1GRIN1GRIN2B | |
| SCHEMBL6089685 | 0.79 | GRIN1 (0.44) | TP53POLBPLA2G2AGRIN1GRIN2B | |
| SCHEMBL5739057 | 0.79 | KMT2A (0.46) | TP53PLA2G2AGRIN1GRIN2BMAPT | |
| SCHEMBL6092460 | 0.79 | RXFP1 (0.44) | TP53POLBPLA2G2ARXFP1MAPT | |
| SCHEMBL6090341 | 0.78 | TP53 (0.43) | TP53POLBPLA2G2ARXFP1GRIN1 | |
| SCHEMBL6091457 | 0.76 | GRIN1 (0.41) | TP53POLBGRIN1GRIN2BMAPT | |
| SCHEMBL6090346 | 0.75 | MAPT (0.42) | TP53POLBRXFP1MAPT | |
| SCHEMBL5738325 | 0.75 | TP53 (0.46) | TP53RXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | IDO1, PTGS1, IDO2 | TP53 2032/4885POLB 3825/4885PLA2G2A 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.